drugset / Trial / NCT05608044
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2027-09
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | — | Intravenous |
| Subject | Botensilimab | Monoclonal antibody | — | Intravenous |
| Comparator | Regorafenib | Small molecule | — | — |
| Comparator | Tipiracil | Small molecule | — | — |
| Comparator | Trifluridine | Small molecule | — | — |